Trabeculectomy with Ologen Combined with Mitomycin-C for the Management of Primary Congenital Glaucoma.

Background: Ologen is a collagen matrix designed to promote wound healing with minimal scarring. It has been used to create a prominent and healthy vascular bleb following trabeculectomy. The purpose of this study is to evaluate the adjunctive use of Ologen with mitomycin-C augmented trabeculectomy in eyes with primary congenital glaucoma. Methods: Ologen was placed in the subconjunctival space and under the scleral flap in 25 eyes of 21 patients with primary congenital glaucoma who underwent trabeculectomy with Mitomycin-C. Patients were examined preoperatively and in the 1st week, 1st, 3rd, 6th and 12th months after surgery. Examination included measurements of the intraocular pressure, corneal diameter, bleb evaluation, and fundus examination. Ultrasound biomicroscopy of the bleb was done at the last follow-up visit. Results: The mean age of the patients was 6.6 ± 2.95 months. Mean preoperative IOP was 22.56 ± 0.83 mmHg and the mean final postoperative IOP was 15.52 ± 3.54 mmHg. Complete success (IOP <21mmHg without medications) was observed in 22/25 eyes (88%) and qualified success of surgery (IOP < 21mmHg with the aid of medications) was observed in 3/25 eyes (12%). Total bleb score was favorable in 8/25 eyes at the end of follow up period. None of the patients experienced systemic or ocular complications that were specifically related to Ologen. Conclusions: Ologen implant is a safe and effective agent in conjunction with Mitomycin-C for improving the long term success rate, bleb survival and function after trabeculectomy surgery. [ABSTRACT FROM AUTHOR]